CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.
  
  OVERVIEW OF ACTIVITY
  The American Cancer Society estimates that in 2019, 22,530 new cases of ovarian cancer will be diagnosed in the United States and 13,980 people will die of the disease. Epithelial ovarian cancer (EOC) comprises approximately 90% of malignant ovarian neoplasms, and this makes EOC the leading cause of death from gynecologic cancer in the United States. The largest recent development in ovarian cancer has been the introduction of poly(ADP-ribose) polymerase (PARP) inhibitors into the therapeutic milieu. Originally developed for and active in cancers with homologous recombination (HR) deficiencies — such as those harboring BRCA1 or BRCA2 mutations — PARP inhibitors have also demonstrated activity in the estimated 50% of ovarian cancer without BRCA1/2 gene mutations but deficient in other DNA repair genes.
  
  Preclinical and clinical studies have suggested that PARP inhibitors may also be active in cancers deficient in signaling pathways that mitigate DNA repair or, in combination with DNA-damaging agents, independent of DNA repair dysfunction. These and other important achievements in the collective understanding of PARP inhibition as a mechanism to combat ovarian cancer development and progression have led to the FDA approval of multiple PARP inhibitors for patients with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutations.
  
  This CME program has been developed from the proceedings of a satellite symposium held during the 2019 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. It features discussions with leading gynecologic cancer researchers regarding challenging cases and the emerging considerations that drive clinical decision-making about the use of PARP inhibitors in the management of ovarian cancer. This activity is designed to assist medical oncologists, gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies by providing information on the latest research developments and their potential application to routine practice.
  
  LEARNING OBJECTIVES
  

  • Recognize the clinical role of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer and a deleterious or suspected deleterious BRCA germline or somatic mutation, and consider how the availability of this strategy affects current therapeutic algorithms.
  • Identify patients with multiregimen-refractory ovarian cancer who may be appropriate candidates for a PARP inhibitor, and safely integrate PARP inhibitors into nonresearch therapy.
  • Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with ovarian cancer, and offer supportive management strategies to minimize and/or ameliorate these side effects.
  • Recall the biologic rationale for and ongoing research efforts evaluating the role of PARP inhibitors in combination with targeted therapy or immunotherapy, and refer appropriate patients for clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Robert L Coleman, MD
  Professor and Executive Director
  Cancer Network Research
  Ann Rife Cox Chair in Gynecology
  Department of Gynecologic Oncology and Reproductive Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee and Contracted Research: AbbVie Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GamaMabs Pharma, Genentech, Genmab, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novartis, Tesaro; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  Professor Jonathan A Ledermann
  Professor of Medical Oncology
  Clinical Director
  University College London Cancer Institute
  Director, Cancer Research UK and UCL Cancer Trials Centre
  London, United Kingdom
  
  Advisory Committee: Artios Pharma, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Cristal Therapeutics, Merck Sharp & Dohme Corp, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics; Contracted Research: AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme Corp; Data and Safety Monitoring Board/Committee: Regeneron Pharmaceuticals Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology.
  
  Stephanie Lheureux, MD, PhD
  Staff, Medical Oncology-Gynecology and Drug Development Program
  Gynecology Site Lead at Princess Margaret Cancer Centre
  Assistant Professor, University of Toronto
  Toronto, Canada
  
  No relevant conflicts of interest to disclose.
  
  Kathleen Moore, MD
  Jim and Christy Everest Endowed Chair in Cancer Research
  Associate Director, Clinical Research
  Director, Oklahoma TSET Phase I Program
  Stephenson Cancer Center
  Associate Professor, Section of Gynecologic Oncology
  Director, Gynecologic Oncology Fellowship
  Department of Obstetrics and Gynecology
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma
  
  Advisory Committee: Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, ImmunoGen Inc, Janssen Biotech Inc, Merck, OncoMed Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc, Samumed, Tesaro, VBL Therapeutics; Contracted Research: Clovis Oncology, Genentech, Merck, PTC Therapeutics, Roche Laboratories Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology and Tesaro.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: June 2019
  Expiration date: June 2020